Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to ...
Too often, leaders treat build and bail as opposites. They believe a company must either grow or retreat, not both. Real ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback